Navigation Links
Parkinson's Patients Still Prescribed Antipsychotics Despite Warning
Date:7/11/2011

MONDAY, July 11 (HealthDay News) -- Antipsychotic drugs are still prescribed to more than half of U.S. patients with Parkinson's disease and psychosis even though a warning that these drugs can worsen Parkinson's symptoms was issued six years ago, a new study reveals.

Many Parkinson's disease patients, including as many as 45,000 in the United States, eventually develop psychosis, meaning their thoughts are sometimes disconnected from reality. Parkinson's disease is also associated with dementia and complications of that condition, which may be exacerbated by antipsychotic drugs, according to the researchers.

In 2005, the U.S. Food and Drug Administration ordered antipsychotic drug packages to carry a "black box" warning about the risks the drugs pose to Parkinson's patients.

In the new study, published in the July issue of the journal Archives of Neurology, researchers analyzed Veterans Affairs data from 2002 to 2008 to assess antipsychotic drug prescription rates among 1,804 Parkinson's disease patients without dementia, 793 Parkinson's patients with dementia, and 6,907 patients with dementia and psychosis but no Parkinson's disease.

The investigators found that about half of the patients with Parkinson's disease and psychosis received an antipsychotic drug prescription. Use of the drugs was higher among patients with both Parkinson's disease and dementia than among those without dementia.

Between 2002 and 2008, the overall rate of antipsychotic prescriptions for Parkinson's patients was unchanged despite the warnings issued in 2005, but there was a decrease in the use of some antipsychotic drugs and an increase in the use of others, Dr. Daniel Weintraub, of the University of Pennsylvania, and colleagues noted in a journal news release.

"Approximately one-third of our Parkinson's disease sample had comorbid dementia, and many more likely had mild cognitive impairment," the authors wrote. "This has significant clinical implications in Parkinson's disease given the increased morbidity and mortality associated with typical and atypical [antipsychotic drug] use in dementia populations."

Even though prescribing habits appeared to shift toward antipsychotic drugs that are better tolerated by Parkinson's disease patients, those drugs are not necessarily safer or more effective, the researchers noted.

The researchers called for further studies to learn more about the factors that contribute to both overall and specific antipsychotic drug use in Parkinson's patients and to examine the effects of antipsychotic drug treatment on illness, death and disease progression in Parkinson's disease patients.

More information

We Move has more about Parkinson's disease.

-- Robert Preidt

SOURCE: Archives of Neurology, news release, July 11, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. ICU Patients at Risk for Rare Heart Rhythm Problem
2. Young patients with chronic illnesses find relief in acupuncture
3. For Some Breast Cancer Patients, Shorter Radiation Works Well
4. New Study Uses Adult Stem Cells in Effort to Save Limbs of Patients with Peripheral Arterial Disease
5. Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration
6. Behavioral therapy improves sleep and lives of patients with pain
7. Protecting patients: Study shows that Johns Hopkins flu vaccination rates twice national average
8. MSU researcher linking breast cancer patients with alternative therapies
9. New American Heart Association Survey Finds Heart Disease and Stroke Patients Face Significant Barriers in Obtaining Quality, Affordable Care
10. Fishy Smell May Keep Patients From Diabetes Drug
11. AGA offers new recommendations for CRC surveillance for certain patients with IBD
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Parkinson's Patients Still Prescribed Antipsychotics Despite Warning
(Date:8/18/2017)... ... August 18, 2017 , ... ... services to communities in east Texas, is launching a regional charity effort to ... Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 ...
(Date:8/18/2017)... Bedford, TX (PRWEB) , ... August 18, 2017 , ... ... serves communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized ... her husband. , In early June of this year, Christina and her children returned ...
(Date:8/18/2017)... ... 2017 , ... Alcovit, a lime-flavored beverage that rids the body of toxins ... product now available through Jet.com. , After 25 years of development, the company ... designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Dangerous Inheritance”: a ... author, Diane Winters. Diane is from Southwest Nebraska where she was raised on ... and family. The story is fictional, but the friendships and mantra of ‘neighbors ...
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, ... yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)...   Marshall County Hospital in Benton, Kentucky has added ... hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ultraviolet ... such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology: